1034 results about "Alcoholic fatty liver" patented technology

The invention relates to application of a polypeptide compound having double agonist effects on a glucagon-like peptide-1 receptor and a glucagon receptor. The polypeptide compound has the characteristics of high enzymolysis stability, high bioactivity, no adverse reaction, etc., can alleviate abnormal rise in the levels of total cholesterol and triglyceride in blood induced by diabetes and high-meal diet, lowers the level of liver enzyme, improves liver damage and fibrosis stage and is applicable to prevention or treatment of diseases like non-alcoholic fatty liver diseases, hyperlipidemia and arteriosclerosis.

Disclosed herein is a novel synergistic pharmaceutical composition comprising hydroxychloroquine with insulin sensitizing agents and lipid lowering agents such as statins along with pharmaceutical excipients / carriers useful in treating Non-Alcoholic Fatty Liver Disease.

The present invention provides a pharmaceutical composition for the prevention and treatment of a non-alcoholic fatty liver disease (NAFLD), containing an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof. Further, the present invention provides a method for the prevention or treatment of a non-alcoholic fatty liver disease, including administering an effective amount of an active ingredient selected from the group consisting of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof to a mammal including a human in need thereof.; Further, the present invention provides use of Compound 1 represented by formula 1, sitagliptin, vildagliptin, linagliptin or a pharmaceutically acceptable salt thereof, for manufacturing a pharmaceutical composition for the prevention or treatment of a non-alcoholic fatty liver disease.

The invention discloses a traditional Chinese medicinal composition for treating alcoholic fatty liver and a preparation method thereof. The traditional medicinal composition contains the following raw materials of: by weight, 15-35 parts of Artemisia capillaries, 15-30 parts of Radix Puerariae, 15-35 parts of Poria cocos, 10-25 parts of couchgrass root, 10-25 parts of Herba Eupatorii, 10-25 parts of cassia seed, 4-10 parts of green tea, 5-12 parts of haw, 5-12 parts of red sage root, 5-12 parts of sweet wormwood, 5-12 parts of cortex lycii, 8-15 parts of burdock, 4-10 parts of Caulis Bambusae In Taeniam, 4-10 parts of polygonatum rhizome, 4-10 parts of ligustrum lucidum, 4-10 parts of Ligusticum wallichii and 2-8 parts of licorice. The traditional Chinese medicinal composition can be made into any clinically acceptable oral medicinal preparation including pill, particulate agent, capsules or tablet and the like. It shows through clinical observation result that the traditional Chinese medicinal composition has substantial curative effects for alcoholic fatty liver. Safety observation indicates that the traditional Chinese medicinal composition is safe in clinic usage and has no toxic and side effect.

The invention belongs to the field of animal experiment models, and discloses application of a composite high-fat forage to construct a non-alcoholic fatty liver disease rat model. The high-fat forage is composed of the following raw materials in percent by mass: 77.5% of a rat basic forage, 10% of egg, 10% of coconut oil, 2% of cholesterol, 0.5% of bile salt, and 500mg / kg / d of sodium valproate calculated according to the rat weight. After 8 weeks, rats all have typical non-alcoholic fatty live symptoms, and liver has a lot of fat accumulation along with inflammatory cell infiltration. The model establishing time is short, the success rate is high, and the composite high-fat forage is applicable to pathogenesis research induced by high-fat-diet combined medicines with liver-toxicity side effect, screening of related control measures and efficacy evaluation of treatment medicines.

Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.

The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.

The invention discloses a semen cassiae, fructus lycii and glossy privet fruit oral solution with functions of tonifying liver and reducing fat. The semen cassiae, fructus lycii and glossy privet fruit oral solution is prepared by adopting the steps of respectively weighing Chinese medicinal herbs: 30 parts of semen cassia, 30 parts of fructus lycii, 30 parts of glossy privet fruit, 20 parts of polygonum multiflorum thumb, 20 parts of gynostemma pentaphylla, 20 parts of raw hawthorn, 20 parts of capillary artemisia, 10 parts of radix curcumae and 10 parts of rhizoma alismatis; and decocting the Chinese medicinal herbs together according to a conventional method, and densely decocting into an oral solution of 2g dried medicinal herbs / ml. A taking method is as follows: the semen cassiae, fructus lycii and glossy privet fruit oral solution is taken twice, 20ml per time. One month is a course of treatment, and the semen cassiae, fructus lycii and glossy privet fruit oral solution is generally taken for three courses of treatment. Fatty, sweet, stodgy and pungent foods are contraindicated in a taking process. The semen cassiae, fructus lycii and glossy privet fruit oral solution has the advantages of low Chinese medicinal herb price, and is convenience to take and process, and has a remarkable treatment effect on non-alcoholic fatty liver disease and hyperlipoidemia. Meanwhile, according to the characteristic of liver deficiency, the semen cassiae, fructus lycii and glossy privet fruit oral solution is suitable for all types of syndrome of the traditional Chinese medicine, is capable of recovering the function of the liver to protect the liver and is capable of removing pathological products to achieve the treatment purpose.